175 related articles for article (PubMed ID: 1547417)
1. Cost benefits of low dose subcutaneous erythropoietin in patients with anaemia of end stage renal disease.
Stevens ME; Summerfield GP; Hall AA; Beck CA; Harding AJ; Cove-Smith JR; Paterson AD
BMJ; 1992 Feb; 304(6825):474-7. PubMed ID: 1547417
[TBL] [Abstract][Full Text] [Related]
2. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group.
BMJ; 1990 Mar; 300(6724):573-8. PubMed ID: 2108751
[TBL] [Abstract][Full Text] [Related]
3. A study of recombinant human erythropoietin in the treatment of anaemia of chronic renal failure in children on haemodialysis.
Van Damme-Lombaerts R; Broyer M; Businger J; Baldauf C; Stocker H
Pediatr Nephrol; 1994 Jun; 8(3):338-42. PubMed ID: 7917862
[TBL] [Abstract][Full Text] [Related]
4. Stepwise correction of anaemia by subcutaneous administration of human recombinant erythropoietin in patients with chronic renal failure maintained by continuous ambulatory peritoneal dialysis.
Stevens JM; Auer J; Strong CA; Hughes RT; Oliver DO; Winearls CG; Cotes PM
Nephrol Dial Transplant; 1991; 6(7):487-94. PubMed ID: 1922910
[TBL] [Abstract][Full Text] [Related]
5. The use of recombinant human erythropoietin in end stage renal disease.
Conlon PJ; Walshe JJ; O'Donnell R; O'Donohoe A; Spencer R; Donohoe J; Carmody M
Ir J Med Sci; 1993 Jan; 162(1):17-9. PubMed ID: 8440603
[TBL] [Abstract][Full Text] [Related]
6. Transfusion and recombinant human erythropoietin requirements differ between dialysis modalities.
House AA; Pham B; Pagé DE
Nephrol Dial Transplant; 1998 Jul; 13(7):1763-9. PubMed ID: 9681725
[TBL] [Abstract][Full Text] [Related]
7. The use of erythropoietin in renal failure.
Macdougall IC; Hutton RD; Coles GA; Williams JD
Postgrad Med J; 1991 Jan; 67(783):9-15. PubMed ID: 2057440
[TBL] [Abstract][Full Text] [Related]
8. Treatment of transfusion-dependent anaemia of chronic renal failure with recombinant human erythropoietin. A European multicentre study in 142 patients to define dose regimen and safety profile.
Sundal E; Businger J; Kappeler A
Nephrol Dial Transplant; 1991; 6(12):955-65. PubMed ID: 1798595
[TBL] [Abstract][Full Text] [Related]
9. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
[TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of recombinant human erythropoietin to subjects on continuous ambulatory peritoneal dialysis: an erythrokinetic assessment.
Hughes RT; Cotes PM; Pippard MJ; Stevens JM; Oliver DO; Winearls CG; Royston JP
Br J Haematol; 1990 Jun; 75(2):268-73. PubMed ID: 2372513
[TBL] [Abstract][Full Text] [Related]
11. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis.
Winearls CG; Oliver DO; Pippard MJ; Reid C; Downing MR; Cotes PM
Lancet; 1986 Nov; 2(8517):1175-8. PubMed ID: 2877323
[TBL] [Abstract][Full Text] [Related]
12. Androgen therapy for anaemia of chronic renal failure. Indications in the erythropoietin era.
Teruel JL; Aguilera A; Marcen R; Navarro Antolin J; Garcia Otero G; Ortuño J
Scand J Urol Nephrol; 1996 Oct; 30(5):403-8. PubMed ID: 8936631
[TBL] [Abstract][Full Text] [Related]
13. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron.
Silverberg DS; Wexler D; Blum M; Tchebiner JZ; Sheps D; Keren G; Schwartz D; Baruch R; Yachnin T; Shaked M; Schwartz I; Steinbruch S; Iaina A
Nephrol Dial Transplant; 2003 Jan; 18(1):141-6. PubMed ID: 12480972
[TBL] [Abstract][Full Text] [Related]
14. [Multicenter study of darbepoetin alfa in the treatment of anemia secondary to chronic renal insufficiency on dialysis].
Martínez Castelao A; Reyes A; Valdés F; Otero A; López de Novales E; Pallardó L; Tabernero JM; Hernández Jaras J; Lladós F
Nefrologia; 2003; 23(2):114-24. PubMed ID: 12778875
[TBL] [Abstract][Full Text] [Related]
15. A study of the response of elderly patients with end-stage renal disease to epoetin alfa or beta.
Nicholas JC
Drugs Aging; 2004; 21(3):187-201. PubMed ID: 14979736
[TBL] [Abstract][Full Text] [Related]
16. Once weekly subcutaneous administration of erythropoietin in haemodialysis patient.
Hussain R; Naqvi SA
J Pak Med Assoc; 1994 Apr; 44(4):88-90. PubMed ID: 8072130
[TBL] [Abstract][Full Text] [Related]
17. Regulation of iron absorption in iron loaded subjects with end stage renal disease: effects of treatment with recombinant human erythropoietin and reduction of iron stores.
Hughes RT; Smith T; Hesp R; Hulme B; Dukes DC; Bending MB; Pearson J; Raja KB; Cotes PM; Pippard MJ
Br J Haematol; 1992 Oct; 82(2):445-54. PubMed ID: 1419827
[TBL] [Abstract][Full Text] [Related]
18. Clinical experience with Repotin, a locally produced recombinant human erythropoietin, in the treatment of anaemia of chronic renal failure in South Africa.
Swanepoel CR; Moosa MR; Rowland GF; Meyers AM; Botha BP; Smart AJ; Goodman R; Schall R; Keogh HJ; Merrifield EH
S Afr Med J; 1996 Oct; 86(10):1266-9. PubMed ID: 8955732
[TBL] [Abstract][Full Text] [Related]
19. [The effect of hemodialysis and continuous ambulatory peritoneal dialysis on renal anemia].
Stojimirović B; Grujić-Adanja G
Srp Arh Celok Lek; 1997; 125(5-6):163-7. PubMed ID: 9265238
[TBL] [Abstract][Full Text] [Related]
20. Administration of exogenous erythropoietin beta affects lipid peroxidation and serum paraoxonase-1 activity and concentration in predialysis patients with chronic renal disease and anaemia.
Marsillach J; Martínez-Vea A; Marcas L; Mackness B; Mackness M; Ferré N; Joven J; Camps J
Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):347-9. PubMed ID: 17324148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
